{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:33:32Z","timestamp":1780061612334,"version":"3.54.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["Support for development of two PDX models"],"award-info":[{"award-number":["Support for development of two PDX models"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Serous endometrial cancer (SEC) is a genomically and morphologically distinct endometrial cancer (EC) subtype with a poor progression-free and overall survival. The development of novel therapies is needed to improve outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used serous and serous-like EC patient-derived xenografts (PDXs) to test a novel drug combination in vitro and in vivo: rucaparib and pegylated SN-38 (PLX038A). Sensitivity to treatment was correlated with indicators of homologous recombination (HR) deficiency. Efficacy in fresh primary patient tumors was also tested ex vivo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Five of eight PDXs had genomic instability scores\u2009\u2265\u200942, but only one of these five had evidence of HR deficiency in assays of irradiation-induced RAD51 foci formation. Moreover, PARP inhibitor (PARPi) monotherapy failed to induce regressions in any of the five SEC models treated with rucaparib in vivo, suggesting limited clinical activity of PARPi in SEC. In further studies, we assessed the response of these models to the sustained release topoisomerase 1 inhibitor, PLX038A, as monotherapy and in combination with rucaparib ex vivo and in vivo. Results of these studies showed that PLX038A had limited monotherapy activity, but combination therapy induced significant regressions in two of five SEC PDXs and markedly slowed tumor growth in the other three regardless of underlying homologous recombination repair deficiency. In addition, 11 of 20 (55%) primary tumors showed synergy with rucaparib\u2009+\u2009SN-38.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Collectively, these studies identify a set of genomically characterized PDX models for preclinical testing of potential SEC therapies and a therapeutic combination that warrants further preclinical investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03406-7","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:59:50Z","timestamp":1747627190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Xiaonan","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zanfagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conway","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun D.","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V.","family":"Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Colon-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen E.","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina A.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Bakkum-Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"Oberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter J.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura N.","family":"Duffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"1","key":"3406_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3406_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","volume":"94","author":"CA Hamilton","year":"2006","unstructured":"Hamilton CA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642\u20136.","journal-title":"Br J Cancer"},{"issue":"1","key":"3406_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/IGC.0000000000000844","volume":"27","author":"M McGunigal","year":"2017","unstructured":"McGunigal M, et al. Survival differences among uterine papillary Serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: A National Cancer database analysis. Int J Gynecol Cancer. 2017;27(1):85\u201392.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3406_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ygyno.2016.11.042","volume":"144","author":"K Matsuo","year":"2017","unstructured":"Matsuo K, et al. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecol Oncol. 2017;144(2):329\u201335.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3406_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2018.02.022","volume":"149","author":"L Tortorella","year":"2018","unstructured":"Tortorella L, et al. Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol. 2018;149(2):291\u20136.","journal-title":"Gynecol Oncol"},{"issue":"7447","key":"3406_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373.","journal-title":"Nature"},{"key":"3406_CR7","doi-asserted-by":"crossref","unstructured":"Lin DI, et al. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. Gynecol Oncol; 2022.","DOI":"10.1016\/j.ygyno.2021.12.030"},{"issue":"5","key":"3406_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711\u20138.","journal-title":"Lancet Oncol"},{"issue":"20","key":"3406_CR9","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, et al. Randomized phase II trial of Carboplatin-Paclitaxel versus Carboplatin-Paclitaxel-Trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol. 2018;36(20):2044\u201351.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3406_CR10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","volume":"2","author":"CA Shu","year":"2016","unstructured":"Shu CA, et al. Uterine Cancer after Risk-Reducing Salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434\u201340.","journal-title":"JAMA Oncol"},{"issue":"11","key":"3406_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/modpathol.2016.135","volume":"29","author":"KL Ring","year":"2016","unstructured":"Ring KL, et al. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol. 2016;29(11):1381\u20139.","journal-title":"Mod Pathol"},{"key":"3406_CR12","doi-asserted-by":"crossref","unstructured":"Heeke AL et al. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol, 2018. 2018.","DOI":"10.1200\/PO.17.00286"},{"key":"3406_CR13","doi-asserted-by":"crossref","unstructured":"Ashley CW et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol Oncol, 2018.","DOI":"10.1016\/j.ygyno.2018.10.032"},{"key":"3406_CR14","unstructured":"de Jonge MM et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res, 2018."},{"issue":"25","key":"3406_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, et al. Niraparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"key":"3406_CR16","unstructured":"Monk BJ et al. A randomized, phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol, 2022: p. JCO2201003."},{"issue":"25","key":"3406_CR17","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, et al. Olaparib plus bevacizumab as First-Line maintenance in ovarian Cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"3406_CR18","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"3406_CR19","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, et al. Niraparib maintenance therapy in Platinum-Sensitive, recurrent ovarian Cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"10106","key":"3406_CR20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet"},{"issue":"9","key":"3406_CR21","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3406_CR22","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1200\/JCO.2003.12.093","volume":"21","author":"S Wadler","year":"2003","unstructured":"Wadler S, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern cooperative oncology group study E3E93. J Clin Oncol. 2003;21(11):2110\u20134.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3406_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ygyno.2018.07.014","volume":"150","author":"S Nishio","year":"2018","unstructured":"Nishio S, et al. A phase II trial of Irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis. Gynecol Oncol. 2018;150(3):432\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3406_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, et al. Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3406_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/bjc.1998.670","volume":"78","author":"KJ Bowman","year":"1998","unstructured":"Bowman KJ, et al. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer. 1998;78(10):1269\u201377.","journal-title":"Br J Cancer"},{"issue":"7","key":"3406_CR26","first-page":"2860","volume":"6","author":"CA Delaney","year":"2000","unstructured":"Delaney CA, et al. Potentiation of Temozolomide and Topotecan growth Inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000;6(7):2860\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3406_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jnci\/djh005","volume":"96","author":"CR Calabrese","year":"2004","unstructured":"Calabrese CR, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96(1):56\u201367.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3406_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","volume":"6","author":"HD Thomas","year":"2007","unstructured":"Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6(3):945\u201356.","journal-title":"Mol Cancer Ther"},{"key":"3406_CR29","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1074\/jbc.M111.296475","volume":"287","author":"AG Patel","year":"2012","unstructured":"Patel AG, et al. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase inhibitors reflects poisoning of both enzymes. J Biol Chem. 2012;287:4198\u2013210.","journal-title":"J Biol Chem"},{"key":"3406_CR30","doi-asserted-by":"crossref","unstructured":"Murai J et al. Rationale for PARP inhibitors in combination therapy with camptothecins or Temozolomide based on PARP trapping versus catalytic Inhibition. J Pharmacol Exp Ther, 2014.","DOI":"10.1124\/jpet.113.210146"},{"issue":"7","key":"3406_CR31","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1093\/nar\/gku088","volume":"42","author":"BB Das","year":"2014","unstructured":"Das BB, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res. 2014;42(7):4435\u201349.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3406_CR32","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1021\/jm401644v","volume":"57","author":"DV Santi","year":"2014","unstructured":"Santi DV, Schneider EL, Ashley GW. Macromolecular prodrug that provides the Irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation. J Med Chem. 2014;57(6):2303\u201314.","journal-title":"J Med Chem"},{"issue":"8","key":"3406_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.neo.2017.04.007","volume":"19","author":"KA Butler","year":"2017","unstructured":"Butler KA, et al. Prevention of human lymphoproliferative tumor formation in ovarian Cancer Patient-Derived xenografts. Neoplasia. 2017;19(8):628\u201336.","journal-title":"Neoplasia"},{"issue":"5","key":"3406_CR34","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","volume":"20","author":"SJ Weroha","year":"2014","unstructured":"Weroha SJ, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014;20(5):1288\u201397.","journal-title":"Clin Cancer Res"},{"issue":"7809","key":"3406_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434\u201343.","journal-title":"Nature"},{"key":"3406_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki Z, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4:16.","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"3406_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2016.08.328","volume":"143","author":"MM AlHilli","year":"2016","unstructured":"AlHilli MM, et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol. 2016;143(2):379\u201388.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3406_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1006\/gyno.1994.1191","volume":"54","author":"Y Hirai","year":"1994","unstructured":"Hirai Y, et al. Establishment and characterization of human cell lines from a serous papillary adenocarcinoma of the endometrium. Gynecol Oncol. 1994;54(2):184\u201395.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3406_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.bjc.6605448","volume":"102","author":"K El-Sahwi","year":"2010","unstructured":"El-Sahwi K, et al. In vitro activity of Pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer. 2010;102(1):134\u201343.","journal-title":"Br J Cancer"},{"issue":"2","key":"3406_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti I, et al. A rapid and simple method for measuring thymocyte apoptosis by Propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139(2):271\u20139.","journal-title":"J Immunol Methods"},{"issue":"2","key":"3406_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"3406_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41(2):93\u2013141.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"3406_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/0008-5472.CAN-21-0732","volume":"82","author":"A Kanakkanthara","year":"2022","unstructured":"Kanakkanthara A, et al. Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in High-Grade serous ovarian carcinoma. Cancer Res. 2022;82(2):307\u201319.","journal-title":"Cancer Res"},{"issue":"4","key":"3406_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00280-019-03903-5","volume":"84","author":"SD Fontaine","year":"2019","unstructured":"Fontaine SD, et al. Species-specific optimization of PEG\u2009~\u2009SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft. Cancer Chemother Pharmacol. 2019;84(4):729\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3406_CR45","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.1038\/s41598-021-87470-x","volume":"11","author":"AL Oberg","year":"2021","unstructured":"Oberg AL, et al. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Sci Rep. 2021;11(1):8076.","journal-title":"Sci Rep"},{"issue":"1","key":"3406_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0090-8258(85)90228-8","volume":"21","author":"SS Chen","year":"1985","unstructured":"Chen SS. Extrauterine spread in endometrial carcinoma clinically confined to the uterus. Gynecol Oncol. 1985;21(1):23\u201331.","journal-title":"Gynecol Oncol"},{"issue":"15","key":"3406_CR47","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, et al. Homologous recombination deficiency (HRD) score predicts response to Platinum-Containing neoadjuvant chemotherapy in patients with Triple-Negative breast Cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3406_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ygyno.2019.11.028","volume":"156","author":"A Sangtani","year":"2020","unstructured":"Sangtani A, et al. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal Tampon collection. Gynecol Oncol. 2020;156(2):387\u201392.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3406_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12864-018-5177-9","volume":"19","author":"S Lin","year":"2018","unstructured":"Lin S, et al. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas. BMC Genomics. 2018;19(1):841.","journal-title":"BMC Genomics"},{"issue":"1","key":"3406_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol"},{"issue":"16","key":"3406_CR51","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","volume":"69","author":"W Sakai","year":"2009","unstructured":"Sakai W, et al. Functional restoration of BRCA2 protein by secondary mutations in -Mutated ovarian carcinoma. Cancer Res. 2009;69(16):6381\u20136.","journal-title":"Cancer Res"},{"issue":"9","key":"3406_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","volume":"33","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860\u201377.","journal-title":"Ann Oncol"},{"key":"3406_CR53","doi-asserted-by":"crossref","unstructured":"J\u00f6nsson JM et al. Homologous recombination repair mechanisms in serous endometrial Cancer. Cancers (Basel), 2021. 13(2).","DOI":"10.3390\/cancers13020254"},{"issue":"1","key":"3406_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13073-021-00990-z","volume":"14","author":"VF Bonazzi","year":"2022","unstructured":"Bonazzi VF, et al. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Med. 2022;14(1):3.","journal-title":"Genome Med"},{"issue":"8","key":"3406_CR55","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher EM, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68(8):2581\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"3406_CR56","doi-asserted-by":"publisher","first-page":"zcab028","DOI":"10.1093\/narcan\/zcab028","volume":"3","author":"RM Hurley","year":"2021","unstructured":"Hurley RM, et al. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer. 2021;3(3):zcab028.","journal-title":"NAR Cancer"},{"issue":"18","key":"3406_CR57","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-21-0774","volume":"81","author":"K Nesic","year":"2021","unstructured":"Nesic K, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in High-Grade serous ovarian carcinoma. Cancer Res. 2021;81(18):4709\u201322.","journal-title":"Cancer Res"},{"issue":"4","key":"3406_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517\u201325.","journal-title":"Nat Med"},{"issue":"22","key":"3406_CR59","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","volume":"28","author":"PA Konstantinopoulos","year":"2010","unstructured":"Konstantinopoulos PA, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555\u201361.","journal-title":"J Clin Oncol"},{"key":"3406_CR60","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/ncomms4361","volume":"5","author":"G Peng","year":"2014","unstructured":"Peng G, et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun. 2014;5:3361.","journal-title":"Nat Commun"},{"issue":"8","key":"3406_CR61","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.35151","volume":"130","author":"BJ Rimel","year":"2024","unstructured":"Rimel BJ, et al. NRG-GY012: randomized phase 2 study comparing Olaparib, Cediranib, and the combination of Cediranib\/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024;130(8):1234\u201345.","journal-title":"Cancer"},{"issue":"1","key":"3406_CR62","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41467-023-37084-w","volume":"14","author":"A Madariaga","year":"2023","unstructured":"Madariaga A, et al. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. Nat Commun. 2023;14(1):1452.","journal-title":"Nat Commun"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03406-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03406-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03406-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:04:09Z","timestamp":1747631049000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03406-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3406"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03406-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Under the aegis of protocols approved by the Mayo Clinic Institutional Review Board (IRB), all patients gave written consent to participate prior to primary surgery or clinical biopsy for recurrent disease (#09-008768, #15-007262, or #17-007946). All of the animal studies were approved by the Mayo Clinic Animal Care and Use Committee in facilities that are accredited by the American Association of Laboratory Animal Care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Shaun Fontaine and Daniel Santi disclose options\/shares in Prolynx stocks. Gerardo Colon-Otero discloses research support to Mayo Clinic from Seagen and Repare. Jamie Bakkum-Gamez discloses inventor of Mayo Clinic intellectual property which is licensed to Exact Sciences (Madison WI) and may receive royalties, paid to Mayo Clinic. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}